RGC vs. XLV
RGC (Regencell Bioscience Holdings Limited) is a stock, while XLV (State Street Health Care Select Sector SPDR ETF) is Health & Biotech Equities fund tracking the Health Care Select Sector Index. Over the past 3 years, RGC returned -22.17%/yr vs 6.63%/yr for XLV. At a 0.04 correlation, their price movements are largely independent.
Performance
RGC vs. XLV - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, RGC achieves a -47.24% return, which is significantly lower than XLV's -0.85% return.
RGC
- 1D
- 5.42%
- 1M
- -57.05%
- YTD
- -47.24%
- 6M
- -56.12%
- 1Y
- -53.25%
- 3Y*
- -22.17%
- 5Y*
- —
- 10Y*
- —
XLV
- 1D
- 1.41%
- 1M
- 1.98%
- YTD
- -0.85%
- 6M
- -0.97%
- 1Y
- 17.16%
- 3Y*
- 6.63%
- 5Y*
- 5.69%
- 10Y*
- 10.01%
RGC vs. XLV - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
RGC Regencell Bioscience Holdings Limited | -47.24% | 325.10% | -52.95% | -62.35% | -12.43% | 165.42% |
XLV State Street Health Care Select Sector SPDR ETF | -0.85% | 14.50% | 2.47% | 2.07% | -2.08% | 10.65% |
Correlation
The correlation between RGC and XLV is 0.11, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.11 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.03 |
Correlation (All Time) Calculated using the full available price history since Jul 16, 2021 | 0.04 |
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
RGC vs. XLV — Risk / Return Rank
RGC
XLV
RGC vs. XLV - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Regencell Bioscience Holdings Limited (RGC) and State Street Health Care Select Sector SPDR ETF (XLV). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| RGC | XLV | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -1.43 | ||
| Sortino ratioReturn per unit of downside risk | -1.12 | ||
| Omega ratioGain probability vs. loss probability | 1.08 | 1.20 | -0.12 |
| Calmar ratioReturn relative to maximum drawdown | -0.67 | 1.65 | -2.31 |
| Martin ratioReturn relative to average drawdown | -1.26 | 3.89 | -5.14 |
Loading charts...
Drawdowns
RGC vs. XLV - Drawdown Comparison
The maximum RGC drawdown since its inception was -98.82%, which is greater than XLV's maximum drawdown of -39.17%. Use the drawdown chart below to compare losses from any high point for RGC and XLV.
Loading charts...
Drawdown Indicators
| RGC | XLV | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -98.82% | -39.17% | -59.65% |
Max Drawdown (1Y)Largest decline over 1 year | -80.12% | -10.47% | -69.65% |
Max Drawdown (3Y)Largest decline over 3 years | -98.82% | -17.11% | -81.71% |
Max Drawdown (5Y)Largest decline over 5 years | — | -17.11% | — |
Max Drawdown (10Y)Largest decline over 10 years | — | -28.40% | — |
Current DrawdownCurrent decline from peak | -98.74% | -4.20% | -94.54% |
Average DrawdownAverage peak-to-trough decline | -64.85% | -7.12% | -57.73% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 43.23% | 4.42% | +38.81% |
Volatility
RGC vs. XLV - Volatility Comparison
Regencell Bioscience Holdings Limited (RGC) has a higher volatility of 30.22% compared to State Street Health Care Select Sector SPDR ETF (XLV) at 5.27%. This indicates that RGC's price experiences larger fluctuations and is considered to be riskier than XLV based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| RGC | XLV | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 30.22% | 5.27% | +24.95% |
Volatility (6M)Calculated over the trailing 6-month period | 112.48% | 10.68% | +101.80% |
Volatility (1Y)Calculated over the trailing 1-year period | 191.03% | 15.09% | +175.94% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 283.09% | 14.77% | +268.32% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 283.09% | 16.57% | +266.52% |
Dividends
RGC vs. XLV - Dividend Comparison
RGC has not paid dividends to shareholders, while XLV's dividend yield for the trailing twelve months is around 1.66%.
| Position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
RGC Regencell Bioscience Holdings Limited | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
XLV State Street Health Care Select Sector SPDR ETF | 1.66% | 1.60% | 1.67% | 1.59% | 1.47% | 1.33% | 1.49% | 2.17% | 1.57% | 1.47% | 1.60% | 1.43% |
Frequently Asked Questions
RGC and XLV have a correlation of 0.11, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
RGC has higher volatility (30.22%) compared to XLV (5.27%). In terms of maximum drawdown, RGC dropped -98.82% vs XLV's -39.17%.
XLV currently has the higher Sharpe Ratio (1.14 vs -0.29), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for RGC and XLV
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer